Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy
BioSpace
Eli Lilly's new JAK2 inhibitor--which it obtained from the recent acquisition of Ajax Therapeutics--reduced spleen volume by more than a third in 70% of patients with myelofibrosis.
pharminent
June 15, 2026 (Last updated: June 15, 2026)
BioSpace
Eli Lilly’s new JAK2 inhibitor–which it obtained from the recent acquisition of Ajax Therapeutics–reduced spleen volume by more than a third in 70% of patients with myelofibrosis.
